Agency Links:   Home  Contact Us   Help   Site Map
Link to Homepage

Patient/Public Info  |  Regional Services  |  Health Professionals Info  |  About BCCA  |  Research  |  Donating

CA15.3

Reviewed: January 2004

The CA15.3 (Cancer Antigen 15-3) assay uses monoclonal antibodies to detect two antigenic sites associated with breast carcinoma cells. It is used primarily as a marker for cancer of the breast, but may also be elevated in cancers of the stomach, liver, pancreas, lung and ovary. As with other tumour markers, CA15.3 is most useful for serial monitoring.

Non-malignant elevations may be seen in hepatitis and cirrhosis.

CA15.3 is an MEIA assay performed on the Abbott AxSYM. Samples can be serum (preferred) or plasma.

Reference Range = <28 kU/L

Borderline levels = 28-60 kU/L

Interferences: HAMA.


The BC Cancer Agency is a part of the Provincial Health Services Authority .
If you notice a problem with this page, please report it via the Bug Report Form.
Copyright © 2010. BC Cancer Agency. All Rights Reserved. | Terms of Use | Privacy

Unofficial document if printed. Please refer to the following web address for up-to-date information: http://www.bccancer.bc.ca/HPI/CancerManagementGuidelines/TumourMarkers/CA153.htm